Hamlet BioPharma AB (publ) update about the development of brain tumor therapy based on the investigational new drug Alpha1H. Hamlet BioPharma together with its partner Neurochase Ltd. are making progress with the early pre-clinical work for the treatment of brain tumors. Important milestones have been reached during the preclinical assessment.

Hamlet BioPharma is developing a new class of anti-cancer therapeutics for multiple cancer indications based on the discovery of its proprietary drug complex HAMLET ('Human Alpha-lactalbumin Made Lethal to Tumor cells'). HAMLET has shown great promise for the treatment of brain tumors, killing brain tumor cells of different origins and significantly delaying brain tumor growth. The cellular effects are reproduced by Hamlet BioPharma's lead anti-cancer compound Alpha1H, which efficiently kills different brain tumor cells in the laboratory.

The brain and spinal cord constitute the central nervous system (CNS), where vital functions are controlled. Due to a lack of efficient drugs that are suitable for delivery into the central nervous system, brain tumor treatment presents a significant challenge. Unlike other organs, the brain does not easily tolerate invasive procedures, making surgical removal of tumors particularly difficult.

In many cases, the location of tumors within the brain may render them inoperable without causing severe damage to vital neural structures.